Lilly’s Pegilodecakin Fails Pancreatic Cancer Test

Asset came from $1.6bn Armo buy

 
• By Kevin Grogan
  
Forest_Tree
Sequoia falls but Lilly hopes Cypress studies fare better • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D